Zobrazeno 1 - 10
of 45
pro vyhledávání: ''
Autor:
Fengjing Xu, Zhipeng Wang, Yunshu Lu, Qin Ye, Yan Liu, Qiqiang Zhang, Hong Sun, Kejin Wu, Jihui Chen, Hongyu Wang, Shouhong Gao, Fang Bai
Publikováno v:
Cancer Cell International
Cancer Cell International, Vol 21, Iss 1, Pp 1-1 (2021)
Cancer Cell International, Vol 21, Iss 1, Pp 1-1 (2021)
Pemetrexed, a new generation antifolate drug, has been approved for the treatment of locally advanced or metastatic breast cancer. However, factors affecting its efficacy and resistance have not been fully elucidated yet. ATP-binding cassette (ABC) t
Publikováno v:
Cancer Cell International
Cancer Cell International, Vol 21, Iss 1, Pp 1-16 (2021)
Cancer Cell International, Vol 21, Iss 1, Pp 1-16 (2021)
BackgroundOverexpression of ABC transporters is a big challenge on cancer therapy which will lead cancer cells resistance to a series of anticancer drugs. Gedatolisib is a dual PI3K and mTOR inhibitor which is under clinical evaluation for multiple t
Publikováno v:
Molecular Medicine
Molecular Medicine, Vol 26, Iss 1, Pp 1-14 (2020)
Molecular Medicine, Vol 26, Iss 1, Pp 1-14 (2020)
Background: Phenotypic transformation of vascular smooth muscle cells is a key element in vascular remodeling and aortic aneurysm growth. Previously, deletion of several inflammasome components decreased formation of aortic aneurysm (AA) in the Angio
Autor:
Yoshinori Hosoya, Kotaro Yoshimura, Koji Koinuma, Yasunaru Sakuma, Naohiro Sata, Hideyuki Ohzawa, Hisanaga Horie, Hidenori Tsukui, Joji Kitayama, Alan Kawarai Lefor, Hironori Yamaguchi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Background Anti-tumor effects of radiation therapy (RT) largely depend on host immune function. Adenosine with its strong immunosuppressive properties is an important immune checkpoint molecule. Method We examined how intra-tumoral adenosine levels m
Autor:
Seon Yoo Kim, Jae Chul Pyun, Jisu Kim, Hae Yong Ko, Jong Sook Lee, Yusun Park, Hanhee Jo, Misu Lee, Kyung Sik Kim, Mijin Yun, Jee In Chung, Tae Hun Kim
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Background Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide. The only drug currently approved for clinical use in the treatment of advanced HCC is sorafenib. However, many patients with HCC show reduced sensitivi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-16 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-16 (2019)
BackgroundLung cancer (LC) is one of the leading causes of death worldwide, which highlights the urgent need for better therapies. Peroxisome proliferator-activated nuclear receptor alpha (PPARα), known as a key nuclear transcription factor involved
Autor:
Caixia Xu, Zhiheng Liao, Peiqiang Su, Anjing Liang, Yan Peng, Xudong Wang, Yongyong Li, Tongzhou Liang, Dongsheng Huang, Hang Zhou, Xiaoming Yang, Bo Gao, Yuanxin Zhu, Chengjie Lian, Jincheng Qiu, Xianjian Qiu
Publikováno v:
Molecular Medicine
Molecular Medicine, Vol 25, Iss 1, Pp 1-14 (2019)
Molecular Medicine, Vol 25, Iss 1, Pp 1-14 (2019)
Background The protective effect of melatonin against bone metabolism imbalance in osteoporosis (OP) induced by drugs such as retinoic acid (RA) is unclear. The aim of this study was to explore the role of melatonin in bone destruction based on a mou
Autor:
Sixi Wei, Ken Y. Yoneda, Ruiwu Liu, Randy P. Carney, Kevin Yang, Wenwu Xiao, Weijie Ma, Qianping Li, Joyce S Lee, Kit S. Lam, Tianhong Li, Alan Nyugen
Publikováno v:
Journal of Hematology & Oncology
Journal of hematology & oncology, vol 12, iss 1
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-18 (2019)
Journal of hematology & oncology, vol 12, iss 1
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-18 (2019)
Background α3β1 integrin is a promising cancer biomarker and drug target. We previously identified a 9-amino-acid cyclic peptide LXY30 for detecting α3β1 integrin on the surface of live tumor cells. This study was undertaken to characterize LXY30
Autor:
Hejian Zou, Jing Han, Jiucun Wang, Xiaodong Zhou, Hui Zhang, Jing Liu, John D. Reveille, Qi Zhu, Yuan Li, Shifang Ren, Yanyun Ma, Li Jin, Jianxin Gu, Dongyi He
Publikováno v:
Molecular Medicine
Molecular Medicine, Vol 25, Iss 1, Pp 1-7 (2019)
Molecular Medicine, Vol 25, Iss 1, Pp 1-7 (2019)
Background Tumor necrosis factor (TNF) blockers have a high efficacy in treating Ankylosing Spondylitis (AS), yet up to 40% of AS patients show poor or even no response to this treatment. In this paper, we aim to build an approach to predict the resp
Autor:
Wan-Ling Tan, Chee Keong Toh, Quan Sing Ng, Eng Huat Tan, Ravindran Kanesvaran, Darren Wan-Teck Lim, Mei-Kim Ang, Daniel Shao-Weng Tan, Amit Jain, Cindy Lim
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Background Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). Dose dependent side effects can